Invasive Aspergillosis Completed Phase 1 Trials for Olorofim (DB15245)

Also known as: Aspergillosis Invasive

IndicationStatusPhase
DBCOND0031838 (Invasive Aspergillosis)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03340597Assessment of Varying Oral Dosing Regimens for F901318 in Healthy SubjectsOther
NCT02737371Multiple Ascending Oral Dose Study of F901318 in Healthy SubjectsTreatment
NCT02730442Study of Potential for Interaction of Fluconazole With F901318Treatment
NCT02808741Evaluation of Immediate Release TabletTreatment
NCT02342574F901318 Multiple Ascending Dose StudyTreatment
NCT02142153F901318 Single Ascending Dose Study in Healthy Male VolunteersTreatment
NCT02680808Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a ProbeTreatment
NCT02394483Single Ascending Oral Dose Study of F901318Treatment